SATIVEX
DEAD

Serial Number

79266020

Owner

CNX THERAPEUTICS LIMITED

Attorney

MICHAEL T OLSEN

Filing Date

Jul 17, 2019

Add to watchlist:

No watchlists yet
View on USPTO

SATIVEX Trademark

Serial Number: 79266020

SATIVEX is a trademark filed by CNX THERAPEUTICS LIMITED on July 17, 2019. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

CNX THERAPEUTICS LIMITED (3 trademarks)

3 BUNHILL ROW
LONDON EC1Y 8YZ , GB

Entity Type: 24

GW Research Limited (77 trademarks)

Sovereign House,

Entity Type: 98

GW Pharma Limited (40 trademarks)

Sovereign House, Histon

Entity Type: 03

Jazz Pharmaceuticals Research UK Limited (46 trademarks)

Building 730,

Entity Type: 98

Trademark Details

Filing Date

July 17, 2019

Registration Date

Not Registered

Goods & Services

Pharmaceutical and veterinary preparations, namely, for use in treating pain, neuropathic pain, cancer pain, multiple sclerosis, spinal cord injury, bladder dysfunction, peripheral neuropathy, spasticity, cancer and cancer symptoms, perioperative pain, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, hypoxic-ischaemic encephalopathy, symptoms of neurogenic disorders, movement disorders, essential tremors, psychotic disorders, diseases of the central nervous system, stroke and head injuries, motion sickness and chemically induced sickness, spasticity, psychiatric illnesses, post-traumatic stress disorder, neurodegenerative diseases, metabolic disorders, obesity, obesity associated with Type II Diabetes, bulimia, schizophrenia, Crohn's disease, Alzheimer's disease, bone disorders, inflammatory disorders, sleep and sleep disorders, and drug, alcohol, and nicotine abuse; pharmaceutical preparations for the treatment of neurological conditions and diseases; herbs for medicinal purposes; medicinal herbs; medicinal oils; medicinal infusions, each of the foregoing for use in treating pain, neuropathic pain, cancer pain, multiple sclerosis, spinal cord injury, bladder dysfunction, peripheral neuropathy, spasticity, cancer and cancer symptoms, perioperative pain, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, hypoxic-ischaemic encephalopathy, symptoms of neurogenic disorders, movement disorders, essential tremors, psychotic disorders, diseases of the central nervous system, stroke and head injuries, motion sickness and chemically induced sickness, spasticity, psychiatric illnesses, post-traumatic stress disorder, neurodegenerative diseases, metabolic disorders, obesity, obesity associated with Type II Diabetes, bulimia, schizophrenia, Crohn's disease, Alzheimer's disease, bone disorders, inflammatory disorders, sleep and sleep disorders, and drug, alcohol, and nicotine abuse; pure extracts of medicinal plants and herbs for pharmaceutical use; foodstuffs for medicinal purposes; herb teas for medicinal purposes; pharmaceutical preparations for the treatment of pain, neuropathic pain, cancer pain, multiple sclerosis, spinal cord injury, bladder dysfunction, peripheral neuropathy, spasticity, oncology, cancer symptoms, psychiatric illnesses, neurodegenerative diseases and metabolic disorders; plant extracts for pharmaceutical purposes

Filing History

CHANGE OF OWNER RECEIVED FROM IB
Mar 5, 2026 CHLD
CHANGE OF NAME/ADDRESS REC'D FROM IB
Dec 11, 2025 ADCH
CHANGE OF OWNER RECEIVED FROM IB
May 31, 2024 CHLD
FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 11, 2024 FINT
FINAL DISPOSITION NOTICE SENT TO IB
Feb 12, 2024 FICS
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Feb 10, 2024 FICR
ABANDONMENT NOTICE MAILED - AFTER EX PARTE APPEAL
Feb 10, 2023 MAB3
ABANDONMENT NOTICE MAILED - AFTER EX PARTE APPEAL
Feb 10, 2023 MAB3
ABANDONMENT - AFTER EX PARTE APPEAL
Jan 23, 2023 ABN3
EXPARTE APPEAL TERMINATED
Jan 23, 2023 EXPT
INTERNATIONAL REGISTRATION RENEWED
Jan 5, 2023 RNWL
EXPARTE APPEAL DISMISSED - FAILURE TO FILE BRIEF
Dec 9, 2022 EXFB
NOTIFICATION OF SUBSEQUENT FINAL EMAILED
Aug 17, 2022 GNS1
SUBSEQUENT FINAL EMAILED
Aug 17, 2022 GNSF
SUBSEQUENT FINAL REFUSAL WRITTEN
Aug 17, 2022 CFRC
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 6, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 5, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 5, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 3, 2022 GNRN
NON-FINAL ACTION E-MAILED
Jan 3, 2022 GNRT
NON-FINAL ACTION WRITTEN
Jan 3, 2022 CNRT
NEW REPRESENTATIVE AT IB RECEIVED
Nov 20, 2021 NREP
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 9, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 9, 2021 CRFA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Nov 9, 2021 CHAN
ASSIGNED TO LIE
Nov 8, 2021 ALIE
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Nov 3, 2021 ERFR
EX PARTE APPEAL-INSTITUTED
Nov 3, 2021 EXPI
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Nov 3, 2021 JURT
EXPARTE APPEAL RECEIVED AT TTAB
Nov 3, 2021 EXAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 15, 2021 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Sep 15, 2021 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sep 15, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sep 15, 2021 REAP
NOTIFICATION OF FINAL REFUSAL EMAILED
May 3, 2021 GNFN
FINAL REFUSAL E-MAILED
May 3, 2021 GNFR
FINAL REFUSAL WRITTEN
May 3, 2021 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 9, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 8, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 8, 2021 TROA
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Feb 13, 2021 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 27, 2021 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jan 27, 2021 OPNR
REFUSAL PROCESSED BY IB
Sep 26, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 10, 2020 RFCS
REFUSAL PROCESSED BY MPU
Sep 9, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 15, 2020 RFCR
NON-FINAL ACTION WRITTEN
Aug 14, 2020 CNRT
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Aug 12, 2020 RFWR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 31, 2020 RFCR
NON-FINAL ACTION WRITTEN
Jul 30, 2020 CNRT
ASSIGNED TO EXAMINER
Jul 28, 2020 DOCK
ASSIGNED TO EXAMINER
Sep 21, 2019 DOCK
APPLICATION FILING RECEIPT MAILED
Sep 10, 2019 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 4, 2019 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Aug 26, 2019 LIMI
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Aug 22, 2019 SDRC